Company news
Psyence Biomedical Ltd. news in 2026
Psyence Biomedical Ltd.'s news releases, calls and decks from 2026, newest first.
Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met
October 21, 2026
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
October 5, 2026
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
September 28, 2026
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
May 15, 2026
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
April 23, 2026
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
April 19, 2026
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
April 17, 2026
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
April 7, 2026
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
March 10, 2026
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
March 3, 2026
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
February 20, 2026
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
February 17, 2026
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
February 13, 2026
Psyence BioMed Announces Settlement of Shareholder Litigation
February 11, 2026
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
January 28, 2026
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
January 22, 2026
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
January 20, 2026
Interim Financials – September 30 2025
January 13, 2026
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
January 12, 2026
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
January 5, 2026
Decks in 2026
- Investor Presentation (August 2026)
Investor deck · 23 slides · Aug 6, 2026